Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.47 |
| ▸ | LPL | P06858 | 7/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015367 | 0.89 | LIPG (0.56) | LIPGLPLDGAT1ENPP3LDHA | |
| SCHEMBL18015329 | 0.89 | LIPG (0.57) | LIPGLPLDGAT1ENPP3LDHA | |
| SCHEMBL18015447 | 0.88 | LIPG (0.47) | LIPGLPLDGAT1LDHAPDGFRB | |
| SCHEMBL19794344 | 0.85 | LIPG (0.42) | LIPGLPLDGAT1ADORA1PDGFRB | |
| SCHEMBL18015347 | 0.83 | LIPG (0.58) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL21397945 | 0.81 | LIPG (0.45) | LIPGLPLDGAT1ENPP3LDHA | |
| SCHEMBL19933764 | 0.80 | LIPG (0.40) | LIPGLPLDGAT1LDHAPDGFRB | |
| SCHEMBL19933638 | 0.80 | LIPG (0.46) | LIPGLPLDGAT1ENPP3LDHA | |
| SCHEMBL21390894 | 0.80 | DGAT1 (0.53) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL19801337 | 0.80 | LIPG (0.41) | LIPGLPLDGAT1LDHAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | MERCK PATENT GMBH | 2021-01-12 | — | — | US | disclosed |
| US-20200052213-A1 | BINUCLEAR METAL COMPLEXES AND ELECTRONIC DEVICES, IN PARTICULAR ORGANIC ELECTROLUMINESCENT DEVICES CONTAINING SAID METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-02-13 | — | — | US | disclosed |
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-07-04 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | PARN, PUF60, PARG | LIPG 4374/4885LPL 4558/4885DGAT1 2586/4885 |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | PARN, PUF60, PARG | LIPG 4374/4885LPL 4558/4885DGAT1 2586/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | LIPG 3693/4885LPL 3416/4885DGAT1 1328/4885 |
| US-20200052213-A1 | BINUCLEAR METAL COMPLEXES AND ELECTRONIC DEVICES, IN PARTICULAR ORGANIC ELECTROLUMINESCENT DEVICES CONTAINING SAID METAL COMPLEXES | BICRA, NCLN, IMMT | LIPG 3633/4885LPL 3762/4885DGAT1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.